Legal & General Group PLC Selecta Biosciences Inc Transaction History

Legal & General Group PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.02 - $1.23 $872 - $1,051	-855 Reduced 6.85%	11,634 $12,000
Q2 2023 Aug 14, 2023	BUY	$1.04 - $1.4 $12,988 - $17,484	12,489 New	12,489 $13,000
Q2 2022 Aug 22, 2022	SELL	$0.67 - $1.4 $6,373 - $13,316	-9,512 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$2.82 - $5.01 $7,523 - $13,366	2,668 Added 38.98%	9,512 $40,000
Q1 2021 May 17, 2021	SELL	$2.92 - $5.07 $984 - $1,708	-337 Reduced 4.69%	6,844 $31,000
Q3 2020 Nov 13, 2020	SELL	$2.18 - $2.84 $5,792 - $7,545	-2,657 Reduced 27.01%	7,181 $18,000
Q2 2020 Aug 14, 2020	BUY	$1.83 - $4.06 $18,003 - $39,942	9,838 New	9,838 $28,000
Q3 2019 Nov 13, 2019	SELL	$1.6 - $2.08 $10,132 - $13,172	-6,333 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$1.47 - $3.06 $5,369 - $11,178	3,653 Added 136.31%	6,333 $15,000
Q2 2018 Aug 10, 2018	BUY	$9.36 - $13.25 $2,527 - $3,577	270 Added 11.2%	2,680 $36,000
Q1 2018 May 17, 2018	SELL	$8.49 - $11.82 $7,776 - $10,827	-916 Reduced 27.54%	2,410 $25,000
Q4 2017 Feb 13, 2018	BUY	$8.97 - $23.38 $29,834 - $77,761	3,326	3,326 $33,000

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.